Abstract: Disclosed herein are rubidium elution systems comprising a primary assembly including a 82Sr/82Rb generator, an activity detector, a waste container, a pump system, a sensor, a tubing circuit, at least one valve, and a computer; and a dose calibrator outside the primary assembly. The system may have an interface for configuring the dose calibrator, and a locking means for preventing access to the interface and reconfigurations of its parameters. Moreover, the dose calibrator may be in electronic communication with the computer of the system. Furthermore, the electronic communication can be embodied with an electronic cable having a breakaway connector. Also, the dose calibrator may be positioned on a mobile platform.

Abstract: A radioisotope elution system is provided, that has at least a component comprised in a cabinet and accessible via a door equipped with an authentication system to ensure safety. The system may also have a user interface equipped with an authentication system. It is also provided a radioisotope elution system that has a dose calibrator equipped with a lifting mechanism for lifting and/or lowering the vial to be tested in the dose calibrator. Advantageously, the lifting mechanism may be controlled for preventing the vial from being lifted during a quality control test on a sample of eluate in the vial. This feature prevents a user from tampering and/or interfering with the vial while a quality control testing is in progress. In another feature, there is provided a radioisotope elution system with a scanning system for entering information about the radioisotope generator and/or the patient in the system. Systems ensuring that the eluant reservoir contains a saline solution are proposed.

Abstract: The present invention relates to a stable pharmaceutical composition of tetrofosmin or pharmaceutically acceptable salts thereof. It also relates to a lyophilized non-radioactive kit which upon reconstitution with 99mTc-pertechnetate solution gives a stable 99mTc-tetrofosmin radiopharmaceutical composition. It also provides process for the preparation of said radiopharmaceutical compositions and their use in diagnostic imaging procedures. The compositions provide desirable technical attributes such as stability, high radiochemical purity (RCP) and desired bio-distribution.

Abstract: The present invention relates to a medical radioisotope transport system that securely holds the radiopharmaceutical imaging system or medical elution system to the floor of a vehicle and ensures the protection of the elution system during transportation. The transport system as per the present invention includes at least a floor-mounting device, a support mechanism with transportation plates, and a locking device. The transport system as per the present invention is encompassed with advanced technical and safety features to ensure safe transportation of radiopharmaceuticals ensuring compliance to the regulatory and quality requirements. The transport system as per the present invention is easy to use, and successfully overcome all the complexities involved in prior available methods for transportation of radiopharmaceutical imaging systems or medical radioisotope elution systems.

Abstract: A radioisotope elution system is provided. The radioisotope elution system may comprise a controller that is configured to calculate the available amount of daughter radioisotope at any time during establishment of the equilibrium for decay of the parent radioisotope into its daughter radioisotope. The radioisotope elution system may comprise a controller that is configured to schedule various patient infusions planned for the next following days and weeks in accordance with the available amount of daughter radioisotope on each day. The elution system may also comprise a controller that is connected to the imaging software of a radioisotope imaging device, where the radioisotope imaging device is arranged for imaging the patient or a region of the patient; and the controller is configured to start an image acquisition at a predetermined time.

Abstract: The present invention provides a method of determining whether a subject is suffering or at a risk of developing a peripheral arterial disease via Positron Emitting Tomography (PET) imaging technology. The method comprises administering a PET radionuclide into the subject via automated generation and/or infusion system, performing PET scan of the region of interest, automated assessment of the PET images, performing assessment and suggesting the most appropriate therapeutic and/or management options for the patients based on the severity score, provides an assessment of regional lower proximity perfusion and perfusion reserve, and/or regional and mean standardized uptake values (SUVs). More particularly, the method of image processing identifies the regional differences in SMP (Skeletal muscle perfusion) and SMPR (Skeletal muscle perfusion reserve) across calf muscles at rest and cuff-induced hyperemia.

Abstract: The present disclosure relates in general to nuclear medicine and generators for the production of radiopharmaceuticals for medical use. In particular, present disclosure relates to a generator column that resists high heat such as depyrogenation and sterilization. This allows some steps of the preparation of the column to be performed in a non-sterile environment. This also allows the generator column to be reusable. The present disclosure further describes methods for the preparation of a generator where a parent radioisotope is charged on the column matrix before or after the matrix is loaded in the column.

Abstract: Syringe shield for using a syringe that includes a barrel, a tip and a plunger when manipulating a radioactive solution. The syringe shield includes: a shield body in which the syringe is insertable, the shield body having a window; a first flange at a first open end of the syringe shield; a second flange at a second open end of the syringe shield; wherein the second flange, the shield body, and the window include radiation shielding material, and wherein the tip of the syringe is accessible by the second open end of the syringe shield and the plunger extends outside the first open end when the syringe is inserted in the syringe shield.

Abstract: The present disclosure relates in general to nuclear medicine and generators for the production of radiopharmaceuticals for medical use. In particular, present disclosure relates to a generator column that resists high heat such as depyrogenation and sterilization. This allows some steps of the preparation of the column to be performed in a non-sterile environment. This also allows the generator column to be reusable. The present disclosure further describes methods for the preparation of a generator where a parent radioisotope is charged on the column matrix before or after the matrix is loaded in the column.

Abstract: The present disclosure concerns radiopharmaceutical compositions of radioactive halogenated benzylguanidine (such as radioiodinated MIBG) or a pharmaceutically acceptable salt, hydrate, or solvate thereof. In a preferred embodiment, the composition has at least 97% of radiochemical purity for at least 4 days. Advantageously, the compositions of the present disclosure may be devoid of parabens, which are carcinogenic and yet are used in known radioactive MIBG compositions. The present disclosure also provides processes of preparing a radioactive halogenated benzylguanidine composition. The compositions of the present disclosure can be used in diagnosis and treatment of various diseases.

Abstract: New types of hydroxamic acid-based bifunctional chelators are provided. These chelators are designed to chelate metal ions that can be detected either by their paramagnetic or radioactive properties. Conjugation with peptides or protein can be achieved by the presence of a linker moiety in the molecular structure of these chelators.